Solid Lipid Nanoparticles of Albendazole for Treatment of Toxocara Canis Infection: In-Vivo Efficacy Studies

Author(s): Anjali Kudtarkar, Ujwala Shinde, G. P. Bharkad, Kavita Singh.

Journal Name: Nanoscience & Nanotechnology-Asia

Volume 7 , Issue 1 , 2017

Become EABM
Become Reviewer

Abstract:

The aim of the present study was to develop solid lipid nanoparticles (SLN) of albendazole (ABZ) and evaluate its efficacy in mice model after oral administration. Various solid lipids were screened on the basis of solubility of the drug. SLN of ABZ were prepared by phase inversion temperature method using Compritol 888 ATO as a lipid with Cremophor EL and Tween 80 as surfactants. Effect of lipid concentration and drug con- centration on mean particle size and entrapment efficiency was evaluated. Optimized formulation was characterized by Transmission electron microscopy (TEM), Differential scanning calorimetry (DSC), and X-ray diffraction (XRD). In vitro drug release was evaluated using dialysis bag diffusion technique. The anthelmintic efficacy of ABZ-SLN was evaluated in mice infected with Toxocara canis larvae. The mean particle size of ABZ-SLN was found to be in the range of 116±3.51 nm - 168.3±3.92 nm and entrapment efficiency wer e found to be in the range of 82.99±2.22% -89.72±1.95% depending on the drug concentration. TEM analysis revealed that nanoparticles were almost geometrical in shape. DSC thermograms and XRD pattern revealed amorphinization of ABZ in SLN matrix. In vitro drug release profile of ABZ-SLN in simulated gastrointestinal conditions demonstrated a prolonged release pattern wherein maximum release was found to be 92.66±1.7% in 24hr. The anthelmintic efficacy study confirmed the reduction in larvae count in the liver, lung, brain and kidney. Based on the results it can be concluded that solid lipid nanoparticles of ABZ could be a promising formulation for the treatment of Toxocara canis infection.

Keywords: Toxocara canis, visceral larva migrans, Albendazole, Solid lipid nanoparticle, in vivo efficacy.

Rights & PermissionsPrintExport Cite as


Article Details

VOLUME: 7
ISSUE: 1
Year: 2017
Page: [80 - 91]
Pages: 12
DOI: 10.2174/2210681206666160726164457
Price: $58

Article Metrics

PDF: 3